HDR Brachytherapy for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a treatment where small radioactive seeds are temporarily placed inside the prostate to kill cancer cells. It targets patients whose prostate cancer has come back but hasn't spread. The goal is to see if this focused treatment can reduce side effects compared to treating the whole prostate.
Who Is on the Research Team?
Hans Chung, MD
Principal Investigator
Sunnybrook Health Sciences Centre, Odette Cancer Centre
Are You a Good Fit for This Trial?
Men with isolated local recurrence of prostate cancer after initial radiation therapy, who have a solitary recurrence confirmed by MRI and biopsy, PSA levels below 10 ng/mL, prostate volume under 50cc, good performance status (ECOG 0-1), no metastases on CT/MRI or bone scan, manageable urinary symptoms (IPSS < 15), and no prior extensive prostate treatments like TURP or chemotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive focal salvage HDR prostate brachytherapy using temporary implantation of radioactive seeds
Follow-up
Participants are monitored for acute and late urinary and rectal toxicities, as well as quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Focal Salvage HDR Brachytherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sunnybrook Health Sciences Centre
Lead Sponsor
Canadian Association of Radiation Oncology
Industry Sponsor